AI Summary
The LEGACY03 study by the Oxford Vaccine Group will investigate how lymph nodes respond to flu and COVID-19 vaccines in older and younger adults, aiming to improve vaccine design for different age groups. The study is funded by the Medical Research Council and is seeking participants aged 18-45 or 65 and older. Results will contribute to future vaccine development.
This study will test the responses of cells in lymph nodes before and after immunization with flu and COVID-19 vaccines and compare reactions in older and younger adults.
The new study will measure how lymph nodes respond to vaccines and how this reaction changes as we age Results will contribute to future vaccine design which will offer greater protection to those most vulnerable to diseases such as flu and COVID-19 and also those better suited for younger people Project to be led by Principal Investigator Dr Katrina Pollock, MRC Clinician Scientist in Vaccinology at the Oxford Vaccine Group, based at the Department of Paediatrics, at the University of Oxford £1.95 million funding from the Medical Research Council/UK Research and Innovation, sponsored by the University of Oxford
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
The study is looking to enrol volunteers aged either between 18 to 45 years OR 65 years and over at the time of screening, and will be based at the Centre for Clinical Vaccinology and Tropical Medicine, based at the Churchill Hospital in Oxford. Participants will enrol for 3 months and the results